168 results about "Virus Protein" patented technology

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The invention discloses a paralichthys olivaceus rhabdovirus G protein tandem antigen epitope peptide and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO: 1. The preparation method comprises the following steps: (1) firstly, analyzing structural characteristics of HIRRV-G protein, predicting B cell antigen epitopes of the HIRRV-G protein, screening the antigen epitopes with advantages on the basis of a prediction result, and synthesizing the antigen epitopes; (2) screening a candidate peptide fragment with high affinity through an enzyme-linked immunosorbent assay; and (3) sequentially connecting the high-affinity peptide fragment sequences meeting the requirements by using a GPGPG connexon, cloning the connected sequences into a pET-28a prokaryotic expression vector, and performing induced expression to obtain the tandem antigen epitope peptide. Compared with a full-length G protein, the tandem antigen epitope peptide is smaller in molecular weight, higher in stability and higher in hydrophilicity; a large number of specific antibodies can be induced in fish bodies, and the death rate of the paralichthys olivaceus infected by viruses is remarkably reduced. The method can be used for HIRRV diagnosis detection reagent and subunit vaccine development.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.

The invention relates to a porcine bacterial polysaccharide-viral protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of animal vaccines. The vaccine takes porcine bacterial polysaccharide and virus protein as raw materials, and a polysaccharide-virus protein conjugate is formed through coupling of a biotin-avidin system; wherein the virus protein is selected from one of classical swine fever virus E2 protein, porcine circovirus type 2 Cap protein, porcine pseudorabies virus gD protein and the like, and the porcine bacterial polysaccharide is selected from one of streptococcus suis capsular polysaccharide, porcine pasteurella multocida capsular polysaccharide and the like. The vaccine can simultaneously induce an organism to generate a high-level IgG antibody aiming at porcine bacterium capsular polysaccharide and virus protein, so that synergistic immune protection on porcine bacterium and virus infection is realized, and a broad-spectrum cross immune effect is achieved.

The invention relates to the technical field of molecular generation, and discloses a reverse design method using a molecular spectrum as a medium to be applied to virus protein drug molecules, which comprises the following steps: firstly, constructing a data set containing a molecular SMILES identifier and a corresponding molecular spectrum, and carrying out drug-likeness and false positive preliminary screening on compounds by adopting Lipinski five rules and a PAINS mode; then training a conditional diffusion model, and generating a target molecular spectrum by taking specific drug properties as conditions; the spectrum is mapped into a molecular SMILES structure through a Transform decoder, so that accurate conversion from the spectrum to the molecule is realized; finally, through conformation optimization and stability verification, candidate drug molecules meeting specific treatment requirements are output. The method effectively avoids the invalid structure problem caused by cross-dimension generation, significantly improves the synthesizability and patent medicine potential of generated molecules, and is suitable for efficient molecular design of antiviral drugs, inhibitors and the like.

The invention, in some aspects, relates to compositions comprising modified viral nucleocapsid (N) proteins and their encoding polynucleotides and methods of using such compositions and preparations to increase viral N protein dimerization and / or increase antigenicity of viral immunization preparations.

Described herein is a method of treating, ameliorating, and / or preventing an influenza viral infection in a subject, and / or immunizing a subject against an influenza viral infection, which include parenterally administering to the subject a first composition including a first compound in an amount sufficient to elicit systemic T and / or B cell response(s) against a first influenza virus in the subject; and administering to the subject a second composition including a viral protein of a second influenza virus through an administration route comprising intranasal, inhalational, intratracheal, intrapulmonary, and intrabronchial, in an amount sufficient to result in establishment of tissue-resident T cell(s), tissue-resident B cell(s), mucosal IgA, and / or systemic IgG specific against the influenza viral infection in the subject. Also described are a kit for performing the method, as well as methods and kits for boosting existing immunity against influenza viral infections.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

The present invention provides neutralizing monoclonal antibodies targeting Nipah virus G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out three monoclonal antibodies that can specifically bind to NiV G protein. Antibody epitope competition experiments found that the S1E2 and SB10 monoclonal antibodies among these three antibodies recognize new epitopes of NiV G protein that have not been reported before. In vitro neutralization experiments have demonstrated that these three antibodies have high in vitro neutralizing activity, and can neutralize both NiV-M and NiV-B strains, with the characteristics of high expression and good stability, and can be used to prepare virus detection products such as Nipah and Hendra or drugs for preventing and treating Nipah and Hendra virus diseases.

The invention discloses a Nipah virus F protein monoclonal antibody and application thereof, the antibody comprises an antibody 2D12 and an antibody 3B10, and the Nipah virus F protein monoclonal antibody is prepared from Nipah virus F protein immunogen. The specific anti-Nipah virus F protein monoclonal antibody pair is prepared and detected, the monoclonal antibody pair can be specifically combined with the Nipah virus F protein, is high in titer and good in affinity and has neutralizing activity, and meanwhile, the detection kit prepared on the basis of the antibody pair can effectively carry out Nipah virus detection; and technical support can be provided for treatment, epidemiological monitoring and diagnosis of Nipah virus infection.

The present invention relates to the field of biomedicine technology, and specifically discloses an mRNA based on the CP protein gene of fish nervous necrosis virus, a vaccine, and a preparation method and application thereof. The present invention provides an mRNA of fish nervous necrosis virus, the nucleotide sequence of which is shown in SEQ ID NO: 1, and the structure includes a 5' untranslated region, a signal peptide sequence, an NNV virus antigen coding region, a 3' untranslated region and polyA. The mRNA vaccine contains the ORF sequence of the capsid protein CP gene that is resistant to NNV virus infection. The results of animal safety tests on the fish nervous necrosis virus mRNA vaccine prepared by the present invention show that the vaccine is safe and effective, and is convenient and simple to use clinically, and has broad application prospects in the prevention and control of viral nervous necrosis in marine cultured fish.

The application discloses a binding antibody against SARS-CoV-2 virus N protein and application thereof. The amino acid sequence of the heavy chain variable region of the monoclonal antibody N2E5 protected by the application is shown in SEQ ID NO. 1 in the sequence listing, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 2 in the sequence listing; the amino acid sequence of the heavy chain variable region of the monoclonal antibody N2E5 is shown in SEQ ID NO. 5 in the sequence listing, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 6 in the sequence listing. The kinetic constants K D of N2E5 and N8C6 with the N protein are 1.42*10 ‑8 M and 1.31*10 ‑8 M respectively. The antibody has high affinity with the N protein of the novel coronavirus and can be widely used in a novel coronavirus antibody detection kit and clinical treatment.

Antimicrobial eyewear features frames infused with or coated with antimicrobial additives, thereby offering continuous protection by actively destroying and inhibiting the growth of bacteria, fungi, parasites, and some viruses. The lenses may also have an antibacterial coating that destroys and inhibits bacterial growth. In some examples, the lenses are treated with a specialized strengthening liquid, wherein the liquid contains nano components that release heavy metal ions capable of invading the cell walls of bacteria, leading to bacterial elimination, destroying DNA molecules and proteases within the bacterial cells, denature viral proteins, break DNA chains, and result in cell death. Additionally, the strengthening liquid reduces dehydrogenase activity and interacts with various protein groups within the cell, thereby reducing the activity of these groups and effectively inhibiting the growth of E. coli and other bacteria on the lens surface.

The application discloses an antibody for detecting a novel duck reovirus (NDRV), and relates to the field of animal disease prevention and treatment.The antibody comprises a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is shown as SEQ ID NO.2, and the amino acid sequence of the light chain is shown as SEQ ID NO.4.The novel duck reovirus sigma C protein antibody can be used for directly and rapidly detecting the NDRV sigma C protein in a quick, sensitive and accurate manner when the novel duck reovirus is detected.The antibody can be used for early diagnosis of the NDRV, epidemiological investigation, and antibody screening in vaccine development, and provides an effective tool for preventing and controlling the novel duck reovirus infection.

The invention relates to the technical field of spreading modes of human viruses, in particular to a virus spreading mode prediction model based on interaction of virus protein and human protein, a prediction model construction method and a prediction method. The method specifically comprises the following steps: S1, constructing a training data set of a virus transmission mode; s2, based on the data in the S1, obtaining a virus-human protein interaction prediction result, vectorizing the prediction result by using 0 / 1 coding, and constructing a virus-human protein interaction matrix; and S3, using a machine learning algorithm and a feature selection project to construct and train a virus propagation mode prediction model based on the interaction of the virus protein and the human protein. The method for predicting the virus propagation mode of interaction between the virus protein and the human protein is convenient to use and wide in application range; the method is especially suitable for new viruses or unknown viruses which are not fully researched, and can realize efficient and rapid propagation mode identification.

The application discloses a method for improving the resistance of citrus to Huangyanbing by using ClPsaN gene, comprising the following steps: (1) cloning a VIGS fragment of the citrus ClPsaN gene; (2) constructing two VIGS expression vectors of TRV and CLBV; and (3) transforming the VIGS expression vector into citrus to obtain VIGS plants in which the citrus ClPsaN gene is silenced. According to the method, the VIGS vector of the citrus ClPsaN gene is constructed, then the vector is transformed into citrus, and the obtained citrus plants can obviously show resistance to Huangyanbing. The titer of Huangyanbing, i.e., Huangyanbing yellow vein-illness virus, can be reduced by 22-34%, and the accumulation amount of virus protein can be reduced by 35-50%, so that the incidence of Huangyanbing is significantly reduced. In addition, the TRV silencing of the citrus ClPsaN gene does not affect the phenotype of the citrus plants, and the citrus ClPsaN gene can be used as a candidate gene to be used in the breeding of citrus plants resistant to Huangyanbing by using VIGS silencing, RNA interference and gene editing technologies in cooperation with multiple genes of the citrus plants resistant to or susceptible to Huangyanbing.

The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and / or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and / or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

The invention discloses application of alpha-terpilenol in preparation of a medicine for resisting respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The alpha-terpilenol can inhibit the virus titer of the RSV in vitro, and obviously inhibits the infection of the RSV on cells. The alpha-terpilenol can maintain the normal alveolar structure of a mouse in vivo, inhibit inflammatory response and inhibit the expression of virus F protein in the lung, so that the alpha-terpilenol has remarkable anti-respiratory syncytial virus activity in vivo and in vitro. According to the invention, a new treatment scheme is provided for respiratory syncytial virus infection, and the treatment cost of respiratory syncytial virus infection is reduced.

The invention provides viral vectors on the basis of adeno-associated virus (AAV) for transducing cells with a nucleic acid construct contained in the viral vector for delivery of a nucleic acid construct by the viral vector, which in their capsid proteins contain an insert arranged at an integration site for a peptide insert in viral proteins which integration site is located on a protruding loop of VP1, VP2 and / or VP3. The insert provides the viral vectors with specificity for targeting inner ear cells, especially for delivery of nucleic acid constructs contained in the viral vectors to inner ear cells.

The invention relates to the technical field of biology, in particular to an anti-EB (Epstein-Barr) virus Rta protein antibody as well as an antigen binding fragment and application thereof. The invention provides an antibody capable of specifically recognizing EB (Epstein-Barr) virus Rta protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises complementary determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, and the amino acid sequences of the complementary determining regions are respectively as follows: GFTFSSSYG, ISSSRYT, ARHLLSGTSSFDC, KSLHSNGNTY, YMS and MQSLEYPFT. The antibody or the antigen binding fragment thereof can be used as a positive control and a calibrator in a nasopharyngeal carcinoma in-vitro diagnostic kit, so that the problem of batch-to-batch difference existing in nasopharyngeal carcinoma positive serum is avoided, and the production cost of the nasopharyngeal carcinoma detection kit is reduced.

The invention belongs to the technical field of aquaculture, and relates to a new application of capsaicin, in particular to an application of capsaicin in preparation of drugs and / or feed additives for preventing and treating fish virus infection. The core of the invention lies in that the capsaicin has an obvious protection effect on infection of spring viraemia of carp virus (SVCV), grass carp reovirus (GCRV) and herpesvirus type 2 (CyHV-2), and can obviously inhibit transcription of SVCV, GCRV and CyHV-2 virus genes and expression of virus proteins. The capsaicin-containing feed additive and / or medicine can be used for preventing and treating fish virus diseases, and has the advantages of high protection efficiency and environmental friendliness.

The invention belongs to the technical field of biology, discloses application of serum extracellular vesicular virus protein BOLF1 in predicting nasopharyngeal carcinoma metastasis risk and serving as an anti-tumor target, and particularly discloses application of a reagent for detecting BOLF1 in preparing a product for predicting the nasopharyngeal carcinoma metastasis risk. Through a 4D-DIA proteomics technology, the EBV lysis period protein BOLF1 is identified in serum EVs of a nasopharyngeal carcinoma patient for the first time, and it is found that the EBV lysis period protein BOLF1 is only specifically enriched in a nasopharyngeal carcinoma metastasis patient. A risk scoring model is constructed based on the BOLF1, and it can be known through an ROC curve of the risk scoring model that the model has high accuracy and sensitivity (AUC = 0.77, significantly superior to 0.61 of EBV DNA), and the risk scoring model can be applied to prediction of nasopharyngeal carcinoma metastasis.